phenotypes. Moreover, the TGF-induced invasion and invadopodia formation could be mitigated by the suppression of transgelin. Slug was also downregulated after knockdown of transgelin. Investigation of mRNA expression patterns showed that the epithelial mesenchymal transition and invadopodia formation related genes significantly increased in the patients with higher expression level of transgelin. And those upregulated genes were enriched in focal adhesion and ECM-receptor interaction pathway.
INTRODUCTION AND OBJECTIVES: Inhibition of histone deacetylase (HDAC) 6 by the pan-deacetylase inhibitor panobinostat hinders the refolding of unfolded proteins by increasing the acetylation of molecular chaperones and increases the amount of unfolded proteins. The human immunodeficiency virus (HIV) protease inhibitor ritonavir suppresses proteasomes and inhibits degradation of unfolded proteins. We thought that panobinostat combined with ritonavir would kill bladder cancer cells by causing unfolded proteins to accumulate and thereby inducing endoplasmic reticulum (ER) stress.
METHODS: A panel of bladder cancer cells (UMUC3, T24, J82, 5637) was treated with panobinostat (50-200 nM) and/or ritonavir (25-50 µM). The cell viability and clonogenicity were assessed by MTS assay and colony formation assay. The induction of ER stress and the expression of acetylated histone, acetylated a-tubulin, cyclin D1, and cyclin-dependent kinase (CDK) 4 were assessed using western blot analysis. Flow cytometry was used for annexin V assay, measuring the mitochondrial membrane potential, and cell cycle analysis. Combination indexes were calculated using the Chou-Talalay method.
RESULTS: Panobinostat and ritonavir induced drastic apoptosis (up to 93.7% annexin V-positive cells) and inhibited the growth of bladder cancer cells synergistically (combination index < 1). The combination cooperatively caused depolarization of the mitochondrial membrane potential, confirming that the combination activated the mitochondrial apoptotic pathway. The combination also decreased the expression of cyclin D1 and CDK4, leading to the accumulation of the cells in the sub-G1 fraction. Acetylation of the HDAC6 substrate a-tubulin confirmed the suppression of HDAC6 activity by panobinostat, and the combination was shown to induce ER stress synergistically. This ER stress induction was shown to play a pivotal role in the combination's cytotoxic action because the ER stress inhibitor cycloheximide markedly attenuated the combination-induced apoptosis. Interestingly, we also found that panobinostat-induced histone acetylation was synergistically enhanced by ritonavir, which is another important mechanism of action.
CONCLUSIONS: The combination of panobinostat and ritonavir causes bladder cancer apoptosis by inducing ER stress and increasing histone acetylation synergistically.
Source of Funding: JSPS KAKENHI Grant Number JP18K09183

MP51-09 COBICISTAT, A POTENT CYP3A4 INHIBITOR, ACTS SYNERGISTICALLY WITH OPROZOMIB TO CAUSE ENDOPLASMIC RETICULUM STRESS IN BLADDER CANCER CELLS
Akinori Sato*, Takako Asano, Makoto Isono, Kazuki Okubo, Tokorozawa, Japan INTRODUCTION AND OBJECTIVES: Inducing endoplasmic reticulum (ER) stress is a novel approach to cancer treatment. The nextgeneration proteasome inhibitor oprozomib acts against cancer by increasing the amount of ubiquitinated protein and thereby causing ER stress, but its efficacy as a single agent is limited especially in solid tumors. We thought that inhibition of the intracellular drugdegrading enzyme CYP3A4 by cobicistat would enhance oprozomib's activity and thereby kill bladder cancer cells effectively.
METHODS: The viability and clonogenicity of bladder cancer cells (J82, T24, UMUC3) treated with oprozomib (25-50 nM) and/or cobicistat (20-40 µM) were assessed by MTS assay and colony formation assay. Apoptosis was assayed using flow cytometry. Western blotting was used to evaluate the induction of ER stress (expression of ER stress markers), protein ubiquitination, histone acetylation, and the expression of the autophagy marker light chain 3-II, AMP-activated protein kinase (AMPK), eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1), and histone deacetylases (HDACs).
RESULTS: The combination of oprozomib and cobicistat inhibited the growth of bladder cancer cells synergistically (combination indexes < 1). It also suppressed colony formation significantly (P < 0.05) and induced robust apoptosis synergistically: either 50 nM oprozomib or 40 µM cobicistat caused slight to moderate increases in the amount of annexin V-positive cells, but the combination increased it drastically (up to 89.1% annexin V-positive cells). The combination was shown to cause ubiquitinated protein accumulation and thereby induce ER stress synergistically. Furthermore, we found that the excessively accumulated ubiquitinated proteins aggregated and thereby caused autophagy. The combination-induced ER stress caused dephosphorylation of 4EBP1 by increasing the expression of mammalian target of rapamycin (mTOR) inhibitor AMPK, showing that the combination also inhibited the mTOR pathway. Interestingly, we also found that the combination increased histone acetylation synergistically by decreasing the expression of HDACs 1, 3, and 6.
CONCLUSIONS: The combination of oprozomib and cobicistat inhibits bladder cancer growth by inducing ER stress synergistically. Histone acetylation is also an important mechanism of the combination's action.
